Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $495.00 at Stifel Nicolaus

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by Stifel Nicolaus from $441.00 to $495.00 in a research note issued to investors on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. The Goldman Sachs Group boosted their price target on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research report on Tuesday, September 16th. BMO Capital Markets raised their price objective on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Raymond James Financial initiated coverage on Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 target price on the stock. Finally, Bank of America raised their price target on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Twenty-four equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $448.04.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock opened at $452.00 on Monday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market cap of $59.25 billion, a price-to-earnings ratio of -183.00 and a beta of 0.36. The stock’s 50-day moving average is $444.12 and its 200-day moving average is $341.13. Alnylam Pharmaceuticals has a one year low of $205.87 and a one year high of $484.21.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue for the quarter was up 17.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Dennis A. Ausiello sold 31,448 shares of the business’s stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the sale, the director directly owned 911 shares in the company, valued at $397,724.38. The trade was a 97.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael W. Bonney sold 11,250 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $450.00, for a total value of $5,062,500.00. Following the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. The trade was a 40.10% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 1.8% in the second quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company’s stock valued at $4,336,064,000 after buying an additional 240,534 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company’s stock valued at $1,192,988,000 after acquiring an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company’s stock valued at $946,466,000 after acquiring an additional 185,783 shares during the period. Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock worth $779,857,000 after purchasing an additional 75,936 shares in the last quarter. Finally, Orbis Allan Gray Ltd increased its position in shares of Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after purchasing an additional 486,489 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.